Related Experiment Video
Updated: Jan 14, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A
Mobina Nakhaei Shamahmood1, Abolfazl Miri2, Fatemeh Mezginejad3
1Student Research Committee Birjand University of Medical Sciences Birjand Iran.
Background And Aims:
Acute myeloid leukemia (AML) is the most common acute leukemia, which is associated with high morbidity and mortality, and its incidence rate is increasing. Despite tremendous advancements in AML treatment, managing the condition is still challenging. Receptor kinase inhibitors like sorafenib have recently raised concerns about monotherapy, and combination treatments are now being investigated as a potential therapeutic avenue. To classify medications taken in conjunction with sorafenib and analyze their combined effects, we reviewed the prior research findings.
Methods:
A thorough literature search utilizing several databases, including PubMed, Google Scholar, Scopus, Embase, and Cochrane, yielded 78 relevant articles until October 2023. Search terms including AML, combination, and Sorafenib were utilized during the database search to find relevant papers.
Results:
Complete remission (CR) in the combination of sorafenib with "cytarabine and idarubicin", "Vorinostat and Bortezomib, Clofarabine", "Fludarabine and Busulfan", "5-azacytidine" and "Quizartinib, Midostaurin and Giltertinib" respectively "99% and 94%", "27% and 3%", 66.6%, "45%, 26%, 16%", "71% and 52%". Furthermore, the overall survival (OS) values for the combination of sorafenib with "Quizartinib, Midostaurin, and Giltertinib", "cytarabine, daunorubicin" and "5-azacitidine" were "80%" "62% 45%", and 24%, respectively.
Conclusion:
Accordingly, several studies suggest that sorafenib's anticancer effectiveness may be enhanced with chemotherapy drugs.
More Related Videos
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy